Introduction: JCAHO is an accrediting body for hospitals in the United States. As part of the accreditation process, the JCAHO is initiating a new program called ORYX. The goal of the program is to integrate routinely collected performance measures into the accreditation process. ORYX PLUS is a voluntary accelerated option to the ORYX initiative being undertaken by the Joint Commission and is currently being offered to hospitals. The goal of this program is to support standardization of outcomes measurement across hospitals for comparative purposes. Risk adjustment models will be provided by the JCAHO to insure comparability of data collected by different hospitals and different performance measurement systems. Two perioperative performance measures identified in ORYX PLUS were evaluated. Methods: Data was collected on 4003 cases during the time period 1/1/ 97 to 8/31/98. The numerator of the first performance measure were patients who developed any one of the following adverse outcomes: a central nervous system injury, a peripheral neurological deficit, an acute myocardial infarction complication or had a cardiac arrest within two post procedure days of procedures involving anesthesia administration. The numerator of the second performance measure was intrahospital mortality of patients within two post procedure days of procedures involving anesthesia administration. For our purposes, all surgical procedures involving anesthesia were included in the denominator for both measures. Morbidity and mortality rates were reported on a quarterly basis. Univariate tests were performed using the chi-square test and wilcoxon rank sum test. Statistical significance was defined p < 0.05. Results: The overall morbidity rate was 0.85% and ranged from 0.15% to 1.92% over 7 calendar year quarters. The overall mortality rate was 0.52% and ranged from 0.32% to 0.85% over 7 calendar year quarters. Patients with a serious adverse outcome were more likely to have a greater number of pre-existing comorbidities (mean(sd) 3.2 (2.1) vs. 4.3 (2.2), p<0.001). Other statistically significant factors associated with these events included ASA class (3, 4, or 5), administration of nitrates preoperatively, invasive monitoring, general anesthesia, blood transfusions, and longer anesthesia duration Patients with serious morbidity were more likely to have an unplanned ICU admission, (p < 0.001). Discussion: The mortality and serious morbidity rates were small with small variability from quarter to quarter. A risk-adjusted benchmark for these serious events is important. The routine monitoring of these rates will insure the quality of an anesthesia service stays in statistical control. Ongoing evaluation of contributing factors to the events will also help in refining anesthesia guidelines. However, a significant decrease in these rates is unlikely in this elderly patient population with multiple pre-existing co-morbidities without significant advancements in surgical interventions or life-saving treatment modalities.
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CONTRIBUTING FACTORS TO SERIOUS ADVERSE OUTCOMES

ORYX:
(a kind of gazelle or a small, soft antelope of Africa and Asia with large, lustrous eyes) a new program initiated by the JCAHO with goals to:
• monitor performance measurement data on a continuous basis • identify areas of improvement • verify effectiveness of paradigm shifts • evaluate comparative data across organizations • integrate routinely collected performance measurement data into the accreditation process Hospitals are currently mandated to submit 2 performance measures every quarter to the JCAHO through a performance measurement system reviewed as acceptable by the JCAHO.
ORYX Plus:
An extension of ORYX which is intended to benchmark data across institutions and make data publicly available. Risk models are applied to hospital data and risk-adjusted data is submitted to the ORYX database based on predefined definitions and models. Participation is optional.
PORP (Perioperative Outcomes Research Program SM ):
This unique continuous quality improvement and benchmarking service for the perioperative setting has met the initial criteria for inclusion in the future accreditation process and is included on the Joint Commission's list of acceptable systems. Perioperative Outcomes Research Program SM is committed to meeting future criteria established by JCAHO. The following six measures have been accepted by the Joint Commission for accreditation purposes in connection with the ORYX initiative:
The program is run by Pharmaceutical Outcomes Research, Inc., Buffalo, NY (1-800-248-4244).
VA Western New York Health Care System:
Anesthesia group dedicated to evaluating, documenting, and improving the process and quality of care of it's surgical patients.
Objective:
Two perioperative measures identified in the ORYX PLUS initiative were evaluated in a Veteran's health care system in Western New York using PORP.
METHODS
Population:
Data was collected on all 4003 surgical cases from 1/1/97 to 8/31/98. Rates were calculated quarterly.
Clinical Outcome Measures:
Standardized Rate: Standardized rates were computed by dividing the observed event rate by the risk adjusted event rate. A value 
Statistics:
Evaluation of factors possibly associated with mortality and serious morbidity rates was performed using the chi-square test and wilcoxon rank sum test. Statistical significance was defined as p < 0.05.
Risk adjusted mortality and serious morbidity rates were calculated by incorporating the factors found in the univariate analysis into a multivariable logistic regression model.
RESULTS
CONCLUSIONS
• The morbidity and mortality rates were small with small variability from quarter to quarter. A significant decrease in these rates is unlikely in this elderly patient population with multiple pre-existing comorbidities without significant advancements in surgical intervention or life-saving treatment modalities. However, it is important for these measures to continue to be monitored for any increase in these rates.
• Continually benchmarking these events not only across time within an institution but also across institutions is important because it allows an institution to use statistical quality control methods to identify what is random variation or when an intervention is necessary and allows an institution comparison to national standard. • Risk adjusting clinical outcome measures is important as it is an attempt to compensate for differences in outcomes that are affected by patient or procedure characteristics or severity. 
